Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:38 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 1,736 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo Administration first Clear all

Conditions: Obesity, Overweight, Healthy
Interventions: PF-04620110, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Interventions: Tamsulosin, Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 55 Years to 80 Years · Male only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Biliary Tract Neoplasms
Interventions: Durvalumab, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 810 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 15
States / cities: Los Angeles, California • Orange, California • Washington D.C., District of Columbia + 12 more

Conditions: Ulcerative Colitis
Interventions: BBT-401-1S first and then Placebo, Placebo first and then BBT-401-1S; Drug
Lead sponsor: Bridge Biotherapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 11
States / cities: Sacramento, California • Ventura, California • Boca Raton, Florida + 8 more

Conditions: Migraine Headache
Interventions: High Dose Psilocybin, Low Dose Psilocybin, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Interventions: palbociclib, Cetuximab, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 14
States / cities: La Jolla, California • San Diego, California • Louisville, Kentucky + 7 more

Conditions: Drug-Resistant Epilepsy, Epilepsy, Epilepsy (Treatment Refractory), Epilepsy Comorbidities, Epilepsy, Drug Resistant, Epilepsy, Generalized, Epilepsy, Focal
Interventions: Target optimization using LIFU, Serial LIFU stimulation; Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 21 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Post Operative Pain, Impacted Third Molar Tooth, Muscle Pain
Interventions: Temporo-masseteric Nerve Block Injection, Oral Pain Medications only; Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Obesity
Interventions: Semaglutide 2.4 mg and NNC0165-1875 2.0 mg, Semaglutide 2.4 mg and placebo 2.0 mg, Semaglutide 2.4 mg and NNC0165-1875 1.0 mg, Semaglutide 2.4 mg and placebo 1.0 mg; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 25
States / cities: Birmingham, Alabama • Anaheim, California • Chula Vista, California + 22 more

Conditions: Atopic Dermatitis
Interventions: Pioglitazone, Placebo (for pioglitazone); Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years to 55 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Lower Back Pain Chronic
Interventions: peripheral magnetic stimulation, Home exercise; Device · Behavioral
Lead sponsor: Joe X. Zhang; Federal
Eligibility: 18 Years to 64 Years
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Edwards Air Force Base, California

Conditions: Dravet Syndrome
Interventions: ZX008 (Fenfluramine Hydrochloride), Matching Placebo; Drug
Lead sponsor: Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.; Industry
Eligibility: 2 Years to 18 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 5
States / cities: San Francisco, California • Aurora, Colorado • Chicago, Illinois + 2 more

Conditions: Pancreatic Cancer
Interventions: MORAb-009, Placebo, Gemcitabine; Drug
Lead sponsor: Morphotek; Industry
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 26
States / cities: La Jolla, California • San Diego, California • Vallejo, California + 22 more

Conditions: Friedreich's Ataxia
Interventions: Interferon γ-1b, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 10 Years to 25 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 4
States / cities: Los Angeles, California • Gainesville, Florida • Iowa City, Iowa + 1 more

Conditions: Preclinical Alzheimer's Disease, Early Preclinical Alzheimer's Disease
Interventions: Lecanemab, Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 55 Years to 80 Years
Enrollment: 1,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2031
U.S. locations: 72
States / cities: Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 61 more

Conditions: Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Adenocarcinoma Metastatic, Pancreatic Adenocarcinoma, Pancreatic Adenosquamous Carcinoma
Interventions: Zoldonrasib, Placebo, Oxaliplatin, Leucovorin (Calcium Folinate), 5-Fluorouracil, Irinotecan, Gemcitabine (GEM), Nab-paclitaxel; Drug
Lead sponsor: Revolution Medicines, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 670 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 18
States / cities: Phoenix, Arizona • Tucson, Arizona • New Haven, Connecticut + 14 more

Conditions: Migraine
Interventions: Lasmiditan, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,633 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 14
States / cities: Huntsville, Alabama • Phoenix, Arizona • La Jolla, California + 10 more

Conditions: Schizophrenia Prodrome
Interventions: Glycine, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 13 Years to 35 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Bronchopulmonary Dysplasia
Interventions: Dexamethasone Early, Dexamethasone Late; Drug
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: 13 Days to 15 Days
Enrollment: 371 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1992 – 1994
U.S. locations: 13
States / cities: Palo Alto, California • New Haven, Connecticut • Washington D.C., District of Columbia + 10 more

Conditions: Ulcerative Colitis
Interventions: IMU-838, Placebo; Drug
Lead sponsor: Immunic AG; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 263 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 15
States / cities: Tucson, Arizona • Los Angeles, California • Ventura, California + 12 more

Conditions: Healthy, Sickle Cell Anemia
Interventions: Placebo, PF-07209326; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 16 Years to 70 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 16
States / cities: New Haven, Connecticut • Washington D.C., District of Columbia • Fort Myers, Florida + 6 more

Conditions: Breast Carcinoma, Recurrent Breast Carcinoma, Stage IV Breast Cancer
Interventions: Bevacizumab, Carboplatin, Paclitaxel, Placebo, Trastuzumab; Biological · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 373
States / cities: Jonesboro, Arkansas • Castro Valley, California • Emeryville, California + 236 more

Conditions: Hypertension
Interventions: Nesiritide (BNP), Placebo; Drug
Lead sponsor: John C Burnett; Other
Eligibility: 18 Years to 80 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Obesity, Overweight
Interventions: NNC0174-0833, Semaglutide, Placebo (NNC0174-0833); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Overland Park, Kansas

Search by objective public record fields.

A Multiple Dose Study Of PF-04620110 In Overweight And Obese, Otherwise Healthy Volunteers

Deprescribing Tamsulosin in Older Men

Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)

Efficacy and Safety of BBT-401-1S in Ulcerative Colitis

Psilocybin for the Treatment of Migraine Headache

Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer

Non-Invasive Low Intensity Focused Ultrasound Stimulation for Drug-Resistant Epilepsy

Jaw Muscle Pain Post Wisdom Molar Surgery

A Research Study to Investigate How Well NNC0165-1875 in Combination With Semaglutide Works in People With Obesity

Assessing the Impact of Pioglitazone on Skin Barrier Function in Atopic Dermatitis Patients

Trial to Test the Efficacy of Using Magnetic Fields to Stimulate the Back to Treat Chronic Lower Back Pain.

A 2-Part Study to Investigate the Dose-Ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children ≥ 2 Years Old and Young Adults With Dravet Syndrome

An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer

Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia

AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid

Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

A Study of Lasmiditan (LY573144) Over Four Migraine Attacks

Glycine vs Placebo for the Schizophrenia Prodrome

Dexamethasone Therapy in VLBW Infants at Risk of CLD

Phase 2 Dose-finding IMU-838 for Ulcerative Colitis

Dose Escalation Study of PF-07209326 in Healthy Participants and Participants With Sickle Cell Disease

Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU

Nesiritide in Resistant Hypertension

A Research Study of How NNC0174-0833 Taken With Semaglutide Works in People Who Are Overweight or Obese